PharmClass

Degarelix 80 mg and 120 mg injections are recommended for inclusion on the Medication Assistance Fund (MAF) for treating advanced hormone-dependent prostate cancer with effect from 4 January 2022.

Enzalutamide 40 mg capsule, in combination with androgen deprivation therapy (ADT) is recommended for inclusion on MAF with effect from 1 September 2022 for treating:

• high-risk non-metastatic castration-resistant prostate cancer (nmCRPC);
• metastatic hormone-sensitive prostate cancer (mHSPC); and
• metastatic castration-resistant prostate cancer (mCRPC).

Olaparib 100 mg and 150 mg tablets are recommended for inclusion on MAF with effect from 1 September 2022, for treating patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene BRCA1/2 and/or ATM-mutations (germline and/or somatic) whose disease has progressed following prior treatment with abiraterone or a second-generation anti-androgen. Androgen deprivation therapy (ADT) should be continued.

MAF assistance does not apply to apalutamide 60 mg tablet, darolutamide 300 mg tablet, olaparib 50 mg capsule or cabazitaxel 60 mg/1.5 mL injection for the treatment of prostate cancer.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.